Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications   London   Roots Analysis has announced the addition of “Fc Fusion Therapeutics Market, 2021-2030” report to its list of...